Itolizumab for Acute Graft-Versus-Host Disease

Itolizumab for Acute Graft-Versus-Host Disease The EQUATE study is a Phase 1b trial to evaluate the safety and clinical efficacy of itolizumab for front-line treatment in patients who present with aGVHD.

The study is an open-label dose escalation study in adult patients who present with high risk aGVHD who typically respond poorly to steroids. Patients in this study received up to a total of 5 doses of itolizumab, administered bi-weekly over the course of 10 weeks. The Phase 1b data was presented to the FDA to inform the path forward for the aGVHD program, and the company is now in Pivotal Phase 3 planning and expected to be ready for enrollment in Q4 2021.

Address

San Diego, CA

Telephone

+18582401200

Website

Alerts

Be the first to know and let us send you an email when Itolizumab for Acute Graft-Versus-Host Disease posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Itolizumab for Acute Graft-Versus-Host Disease:

Shortcuts

Share

Category